Neurophet, an artificial intelligence (AI) solution company for brain disease, announced on the "Neurophet AQUA", has obtained 510(k) clearance from U.S. Food and Drug Administration (FDA) for its newly integrated multiple sclerosis (MS) analysis...
Animal models expressing loss-of-function mutations in mitochondrial DNA enable the investigation of mitochondrial gene function and related disorders. In a recent study, scientists from Korea University described the impact of a mitochondrial ND5...
Neurizon Therapeutics Limited a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce positive results from a preclinical study of its lead candidate, NUZ-001. These innovative studies reveal...
Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer's disease, announced that results from its Phase...
Aadi Bioscience, Inc. announced financial results for the third quarter ended September 30, 2024, and provided recent corporate progress. "The third quarter saw strong sales growth for FYARRO, backed by continued account momentum, increased demand...
GoodRx the leading prescription savings platform in the U.S., announced the rollout of its new e-commerce solution, with Opill® as its launch partner. This new seamless direct-to-consumer shopping experience allows consumers to order eligible...
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced that the first participant has been dosed in the Randomized Placebo Controlled Double Blind...
Eisai Saudi Arabia was established in April 2024 in order to build an in-house sales system. Japan-based Eisai Co. has announced that fully-fledged operations and business activities have begun at Eisai Pharmaceuticals Single Person Limited...
nuBioAge, a longevity science and wellness network based in West Palm Beach, has announced a partnership between their new comprehensive assessment and research center, nuHx, and Marius Pharmaceuticals, the company behind KYZATREX® (testosterone...
Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that its research collaborators were selected to present at the upcoming 2024 EORTC-NCI-AACR...
Cygnus Technologies both part of Maravai LifeSciences (NASDAQ: MRVI) have collaborated to launch Cygnus’ AccuRes™ Host Cell DNA Quantification Kits. Together, the companies have leveraged state-of-the-art technologies and reagents to develop an...
Bavarian Nordic A/S announced a new order from HERA (the European Health Emergency Preparedness and Response Authority) for the Company’s MVA-BN® vaccine, the only FDA and EMA-approved mpox vaccine. HERA will procure 175,420 doses of the vaccine...
Citius Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved LYMPHIR™ (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of r/r cutaneous T-cell lymphoma (CTCL) after at least one prior...
Eximia Research announces the integration of Tidewater Clinical Research into its national network of clinical trial sites. This strategic development unites Tidewater's longstanding expertise in Women's Health and Ophthalmology with Eximia's...
AIM ImmunoTech Inc. announced the next CEO Corner segment has been published on the Company’s website. In the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provides an overview of the positive data from the Phase 1 clinical trial...
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Sanofi announced an update to the timing for the anti-TL1A, duvakitug (formerly known as TEV-’574/SAR447189) program investigating the human IgG1-λ2 monoclonal...
T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer's disease (AD), announced that CEO, John Didsbury, will be presenting new Phase 2 results in a...
Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer's disease, announced final results from its Phase...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced the launch of a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the #1 prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with...
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. a clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies for achieving functional cure in chronic hepatitis B (CHB) infection, announced that their...
